These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 15483740

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Antihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trials.
    Xu FY, Yang B, Shi D, Li H, Zou Z, Shi XY.
    Eur J Clin Pharmacol; 2012 Feb; 68(2):195-205. PubMed ID: 21881888
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction.
    Hartog JW, van de Wal RM, Schalkwijk CG, Miyata T, Jaarsma W, Plokker HW, van Wijk LM, Smit AJ, van Veldhuisen DJ, Voors AA.
    Eur J Heart Fail; 2010 Apr; 12(4):397-403. PubMed ID: 20154337
    [Abstract] [Full Text] [Related]

  • 28. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure.
    Neumann J, Ligtenberg G, Oey L, Koomans HA, Blankestijn PJ.
    J Am Soc Nephrol; 2004 Nov; 15(11):2902-7. PubMed ID: 15504943
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Effects of eprosartan on mitochondrial membrane potential and H2O2 levels in leucocytes in hypertension.
    Labiós M, Martínez M, Gabriel F, Guiral V, Ruiz-Aja S, Beltrán B, Muñoz A.
    J Hum Hypertens; 2008 Jul; 22(7):493-500. PubMed ID: 18385744
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
    Levine B.
    Curr Med Res Opin; 2001 Jul; 17(1):8-17. PubMed ID: 11464450
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Management of hypertension: the advent of a new angiotensin II receptor antagonist.
    Hedner T.
    J Hypertens Suppl; 1999 Jun; 17(2):S21-5. PubMed ID: 10465063
    [Abstract] [Full Text] [Related]

  • 37. Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study.
    Garg JP, Ellis R, Elliott WJ, Hasabou N, Chua D, Chertow GM, Bakris GL.
    Am J Nephrol; 2005 Jun; 25(4):393-9. PubMed ID: 16088080
    [Abstract] [Full Text] [Related]

  • 38. Costs of eprosartan versus diuretics for treatment of hypertension in a geriatric population: an observational, open-label, multicentre study.
    Gregori JA, Nuñez JF, Domínguez-Gil A, MEFASA Group.
    Drugs Aging; 2009 Jun; 26(7):617-26. PubMed ID: 19655828
    [Abstract] [Full Text] [Related]

  • 39. Celiac disease-like enteropathy due to antihypertensive therapy with the angiotensin-II receptor type 1 inhibitor eprosartan.
    Maier H, Hehemann K, Vieth M.
    Cesk Patol; 2015 Jun; 51(2):87-8. PubMed ID: 25970720
    [Abstract] [Full Text] [Related]

  • 40. The effect of treatment with eprosartan on pulse pressure: factors predicting response.
    de la Sierra A, Muñoz A, Arcos E, López JS, Relats J, ETAPA-2 study investigators.
    Can J Cardiol; 2004 Oct; 20 Suppl C():17C-22C. PubMed ID: 16807619
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.